Vergoeding 2017-2021 voor ATC-subgroep A10BJ : Glucagonachtig peptide-1-agonisten (glp-1-agonisten)
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| A10BJ01 Exenatide (Bydureon ®) | 1.006.400 | 879.410 | 730.960 | 588.480 | 477.290 |
| A10BJ02 Liraglutide (Victoza ®) | 12.166.300 | 13.666.600 | 13.784.700 | 11.632.600 | 9.263.200 |
| A10BJ03 Lixisenatide (Lyxumia ®) | 51.647 | 90.202 | 83.417 | 65.761 | 43.015 |
| A10BJ05 Dulaglutide (Trulicity ®) | 1.699.200 | 2.757.000 | 2.640.300 | 3.586.600 | 4.397.900 |
| A10BJ06 Semaglutide (Ozempic ®) | . | 380.020 | 9.289.300 | 24.153.100 | 36.065.100 |
| Totaal | 14.923.547 | 17.773.232 | 26.528.677 | 40.026.541 | 50.246.505 |